Disclaimers Do Not Remedy Content Violations – FDA Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Providing disclaimers for material that promotes an uncleared or unapproved use does not remedy content violations, FDA's device center Promotion and Policy Staff emphasize in a Nov. 5 letter to Diomed
You may also be interested in...
FDA Denies WLF Petition To Allow Dissemination Of Off-Label Information
Dissemination of journal reprints representing off-label use of a device or drug will not by themselves trigger FDA enforcement action against a manufacturer, according to the agency
FDA Denies WLF Petition To Allow Dissemination Of Off-Label Information
Dissemination of journal reprints representing off-label use of a device or drug will not by themselves trigger FDA enforcement action against a manufacturer, according to the agency
Internet Device Promotion Policies Still Evolving, PAPS Staffer Wolf Tells FDLI
Password protection on an Internet web site is an acceptable technique to limit viewing audience, but it should not be used in lieu of compliance with content requirements, CDRH officials warn.